Journal of Neuroscience · 2005 · 779 citations · 67 references
Life SciencesNeurosciencePharmacologyNeurochemistryNeurodegenerationNeuropharmacologyAlzheimer DiseaseCannabinoid PharmacologyNeurodegenerative DiseasesNeurodegenerative DisordersNeuroinflammationNeuroprotectionCannabinoid NeuroprotectionCannabinoid Receptor ModulationCannabinoid Receptor PharmacologyGlial-mediated NeurotoxicityNeuronal Injury MarkersNeuroprotective AgentsNeuroprotective PharmacotherapyReceptor-g Protein Coupling
Alzheimer’s disease is marked by β‑amyloid deposition, microglial activation, neuronal loss, and cognitive decline, and cannabinoids have demonstrated neuroprotective effects against excitotoxicity and acute brain injury. The study sought to map cannabinoid receptor distribution and function in AD and to test whether cannabinoids could protect against β‑amyloid–induced damage in vivo and in vitro. CB1 and CB2 receptors are expressed on senile plaques and neurons but show reduced G‑protein coupling and increased nitration in AD, while treatment with cannabinoids (WIN55,212‑2, HU‑210, JWH‑133) blocks microglial activation, mitigates neurotoxicity, preserves neuronal markers, and prevents cognitive impairment, demonstrating that cannabinoids can halt the neurodegenerative process in AD.
Alzheimer's disease (AD) is characterized by enhanced β-amyloid peptide (βA) deposition along with glial activation in senile plaques, selective neuronal loss, and cognitive deficits. Cannabinoids are neuroprotective agents against excitotoxicity in vitro and acute brain damage in vivo . This background prompted us to study the localization, expression, and function of cannabinoid receptors in AD and the possible protective role of cannabinoids after βA treatment, both in vivo and in vitro . Here, we show that senile plaques in AD patients express cannabinoid receptors CB 1 and CB 2 , together with markers of microglial activation, and that CB 1 -positive neurons, present in high numbers in control cases, are greatly reduced in areas of microglial activation. In pharmacological experiments, we found that G-protein coupling and CB 1 receptor protein expression are markedly decreased in AD brains. Additionally, in AD brains, protein nitration is increased, and, more specifically, CB 1 and CB 2 proteins show enhanced nitration. Intracerebroventricular administration of the synthetic cannabinoid WIN55,212-2 to rats prevent βA-induced microglial activation, cognitive impairment, and loss of neuronal markers. Cannabinoids (HU-210, WIN55,212-2, and JWH-133) block βA-induced activation of cultured microglial cells, as judged by mitochondrial activity, cell morphology, and tumor necrosis factor-α release; these effects are independent of the antioxidant action of cannabinoid compounds and are also exerted by a CB 2 -selective agonist. Moreover, cannabinoids abrogate microglia-mediated neurotoxicity after βA addition to rat cortical cocultures. Our results indicate that cannabinoid receptors are important in the pathology of AD and that cannabinoids succeed in preventing the neurodegenerative process occurring in the disease.
67
Cannabinoid receptor localization in brain.
Miles Herkenham, A B Lynn, M.D. Little et al. · Proceedings of the National Academy of Sciences · 1990 · 2.3K citations
SR141716A, a potent and selective antagonist of the brain cannabinoid receptor
Murielle Rinaldi‐Carmona, Francis Barth, Michel Héaulme et al. · FEBS Letters · 1994 · 1.8K citations · Full text
Medicine, Neuroscience, Pharmacology +14
Activation of microglial cells by β-amyloid protein and interferon-γ
Lucia Meda, Marco A. Cassatella, Györgyi I. Szendrei et al. · Nature · 1995 · 1.3K citations